SEARCH OUR PAGES

Autoimmune Diseases

Autoimmune Diseases

Autoimmune Diseases Pipeline

OSE Immunotherapeutics’ autoimmune diseases pipeline consists of two clinical-stage programs with promising candidates focusing on two different pathways: the CD28 pathway with FR104 and the IL7 pathway with OSE-127.

Both products are partnered with pharmaceutical companies: FR104 with Janssen Biotech (Johnson & Johnson) for its development in autoimmune diseases and particularly in rheumatoid arthritis, and OSE-127 with Servier Laboratories for its development in ulcerative colitis and Sjögren syndrome.

Program
Indication
Humanized
lead
Pre-Clinical
POC
Phase 1
Phase 2
Phase 3
Partners
AUTO-IMMUNE DESEASES
FR104
CD-28
Rheumatoid
arthritis
2019
OSE-127
IL-7 R
UC Sjögren
2018

Program

  • Indication Rheumatoid
    arthritis
  • Humanized
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 2019
  • Phase 3
  • Partners
  • Indication UC Sjögren
  • Humanized
  • Pre-Clinical POC
  • Phase 1 2018
  • Phase 2
  • Phase 3
  • Partners
  • OSE-127

    +
  • FR104

    +